title: Movement disorder emergencies in childhood.
abstract: The literature on paediatric acute-onset movement disorders is scattered. In a prospective cohort of 52 children (21 male; age range 2mo-15y), the commonest were chorea, dystonia, tremor, myoclonus, and Parkinsonism in descending order of frequency. In this series of mainly previously well children with cryptogenic acute movement disorders, three groups were recognised: (1) Psychogenic disorders (n = 12), typically >10 years of age, more likely to be female and to have tremor and myoclonus (2) Inflammatory or autoimmune disorders (n = 22), including N-methyl-d-aspartate receptor encephalitis, opsoclonus-myoclonus, Sydenham chorea, systemic lupus erythematosus, acute necrotizing encephalopathy (which may be autosomal dominant), and other encephalitides and (3) Non-inflammatory disorders (n = 18), including drug-induced movement disorder, post-pump chorea, metabolic, e.g. glutaric aciduria, and vascular disease, e.g. moyamoya. Other important non-inflammatory movement disorders, typically seen in symptomatic children with underlying aetiologies such as trauma, severe cerebral palsy, epileptic encephalopathy, Down syndrome and Rett syndrome, include dystonic posturing secondary to gastro-oesophageal reflux (Sandifer syndrome) and Paroxysmal Autonomic Instability with Dystonia (PAID) or autonomic 'storming'. Status dystonicus may present in children with known extrapyramidal disorders, such as cerebral palsy or during changes in management e.g. introduction or withdrawal of neuroleptic drugs or failure of intrathecal baclofen infusion; the main risk in terms of mortality is renal failure from rhabdomyolysis. Although the evidence base is weak, as many of the inflammatory/autoimmune conditions are treatable with steroids, immunoglobulin, plasmapheresis, or cyclophosphamide, it is important to make an early diagnosis where possible. Outcome in survivors is variable. Using illustrative case histories, this review draws attention to the practical difficulties in diagnosis and management of this important group of patients.
authors.affiliation: Southampton University Hospitals NHS Trust, UK. fk@soton.ac.uk
authors.forename: F J
authors.initials: FJ
authors.lastname: Kirkham
authors.forename: P
authors.initials: P
authors.lastname: Haywood
authors.forename: P
authors.initials: P
authors.lastname: Kashyape
authors.forename: J
authors.initials: J
authors.lastname: Borbone
authors.forename: A
authors.initials: A
authors.lastname: Lording
authors.forename: K
authors.initials: K
authors.lastname: Pryde
authors.forename: M
authors.initials: M
authors.lastname: Cox
authors.forename: J
authors.initials: J
authors.lastname: Keslake
authors.forename: M
authors.initials: M
authors.lastname: Smith
authors.forename: L
authors.initials: L
authors.lastname: Cuthbertson
authors.forename: V
authors.initials: V
authors.lastname: Murugan
authors.forename: S
authors.initials: S
authors.lastname: Mackie
authors.forename: N H
authors.initials: NH
authors.lastname: Thomas
authors.forename: A
authors.initials: A
authors.lastname: Whitney
authors.forename: K M
authors.initials: KM
authors.lastname: Forrest
authors.forename: A
authors.initials: A
authors.lastname: Parker
authors.forename: R
authors.initials: R
authors.lastname: Forsyth
authors.forename: C M
authors.initials: CM
authors.lastname: Kipps
mesh_terms: D000208:Acute Disease; D020274:Autoimmune Diseases of the Nervous System / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D020739:Brain Diseases, Metabolic, Inborn / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D002648:Child; D015897:Comorbidity / Q000639:trends; D004409:Dyskinesia, Drug-Induced / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D004632:Emergency Medical Services / Q000592:standards; D006801:Humans; D009069:Movement Disorders / Q000401:mortality* / Q000503:physiopathology* / Q000628:therapy; D011602:Psychophysiologic Disorders / Q000401:mortality / Q000503:physiopathology / Q000628:therapy